AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25295770
Drug: Activity prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity prescription intervention targeting both exercise and sedentary intensity
Trial: 15500257
Drug: Comfrey extract
RxNorm normalized name: comfrey leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfrey extract ointment (Kytta-Salbe f, four treatments per day for 8 days)
Trial: 8985298
Drug: Lamivudine 25
RxNorm normalized name: LAMIVUDINE 25MG/5ML SOLN,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 25 mg daily
Trial: 7872992
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment for one week
Trial: 9555615
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for one week
Trial: 15738010
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of gentamicin (5.1 mg/kg every 24 hours; n = 18)
Trial: 15738010
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of gentamicin (120 mg followed by 80 mg every 8 hours; n = 20)
Trial: 15738010
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of gentamicin
Trial: 15738010
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of gentamicin
Trial: 21752101
Drug: Methylprednisolone plus
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone plus Mycophenolate mofetil (3 g/day, 1.5 g twice daily)
Trial: 15623591
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg daily
Trial: 12519419
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) treatment (0.04 U/kg/day for 14 weeks preoperatively and doubled for the first 2 weeks postoperatively)
Trial: 3097099
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of recombinant tissue-type plasminogen activator (rt-PA)
Trial: 29843467
Drug: New HM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New HM fortifier (nHMF; n = 26) containing 12.5 g medium‐chain FA, 958 mg linoleic acid, 417 mg α‐linolenic acid, and 157 mg docosahexaenoic acid per 100 g of powder
Trial: 8396087
Drug: Azithromycin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (n = 252) 500 mg once daily for three days
Trial: 8396087
Drug: Clarithromycin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (n = 258) 250 mg twice daily for ten days
Trial: 25596108
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy to the anorectum and rectum
Trial: 15504839
Drug: SR clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SR clarithromycin (500 mg daily)
Trial: 8116811
Drug: Halofantrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (3 doses of 500 mg each at 4-hr intervals on the first day, followed by 500 mg a day for six days; total dose 4.5 g)
Trial: 20673731
Drug: Open reduction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open reduction, rigid internal fixation, and functional treatment
Trial: 17106197
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg once a day, increased to 100 mg twice a day after 10 days if tolerated)
Trial: 14739814
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine analgesia
Trial: 8112185
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg miglitol 3 times a day
Trial: 8112185
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg miglitol 3 times a day
Trial: 28808771
Drug: Classical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical treatment (antibiotics, anti-inflammatories and low-fibre diet)
Trial: 28808771
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (anti-inflammatories and low-fibre diet)
Trial: 27656713
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily for four months
Trial: 14767999
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and hypertonic saline (30%) infusion to maintain serum sodium levels of 145‐155 mmol/L (Group 2)
Trial: 9296466
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (dalteparin sodium, Fragmin)
Trial: 8095362
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with haloperidol, chlorpromazine, and perphenazine
Trial: 29764602
Drug: Minimally adequate
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally adequate treatment for psychiatric disorders
Trial: 25675385
Drug: Saline (0.9%)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (0.9%) infusion
Trial: 25675385
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human TNF‐α (1000 ng/m(2) · h) infusion
Trial: 10371400
Drug: Ethanol 0.8
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.8 g/kg
Trial: 6125195
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg metoprolol
Trial: 25917008
Drug: Exposure Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure Therapy (ET)
Trial: 15781541
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL saline (placebo)
Trial: 12559267
Drug: 11 mL
RxNorm normalized name: camphor 0.11 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 mL of 0.2% oxybuprocaine hydrochloride gel
Trial: 10342416
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three opioids (morphine, pethidine, fentanyl)
Trial: 2681675
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate mouthrinse (CHx) used twice daily for 6 weeks
Trial: 30952941
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment
Trial: 12675873
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors (urinary protein ≥3 g/day and systolic blood pressure ≥140 mm Hg)
Trial: 11140330
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon alpha (IFN-alpha) treatment
Trial: 8243376
Drug: Felbamate (FBM)
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate (FBM) as monotherapy
Trial: 8243376
Drug: Felbamate (FBM)
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate (FBM) as add-on therapy
Trial: 2869850
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of catecholamines with alpha 2 agonist activity (60-120 min)
Trial: 27741949
Drug: Hydrocortisone 50
RxNorm normalized name: hydrocortisone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 50 mg every 6 hours
Trial: 25335327
Drug: Mecobalamine Tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecobalamine Tablet, 500 microg each time, 3 times per day
Trial: 12356155
Drug: Combined electrocautery
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined electrocautery pencil and suction with intravenous infusion catheter
Trial: 10358229
Drug: Alcoholic solution
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic solution
Trial: 7049308
Drug: Preoperative intraparietal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative intraparietal (intra-incisional) injection of cefoxitin
Trial: 26783095
Drug: Ranibizumab monthly
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monthly
Trial: 17902186
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Ginkgo biloba extract (GBE)
Trial: 15139796
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 6.9 mg [14C]ciclesonide
Trial: 15139796
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.64 mg [14C]ciclesonide
Trial: 9747866
Drug: CAF (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (cyclophosphamide, doxorubicin, and 5-flurouracil) dose-intensive treatment
Trial: 29161199
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray
Trial: 31006955
Drug: Lidocaine-Propitocain Cream
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine-Propitocain Cream (EMLA)
Trial: 16616164
Drug: manualized 24-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manualized 24-session treatment incorporating motivational interviewing and emotion coping and communication skills
Trial: 12865901
Drug: Pentagastrin (cholecystokinin-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentagastrin (cholecystokinin-B receptor agonist)
Trial: 21684088
Drug: Multidimensional Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional Family Therapy (MDFT)
Trial: 24632279
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) treatment in patients with DM and type A/B1 lesions
Trial: 24632279
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) treatment in patients without DM and type A/B1 lesions
Trial: 19101456
Drug: HPV‐16/18 AS04‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐16/18 AS04‐adjuvanted vaccine
Trial: 17655704
Drug: Simvastatin administered
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin administered during two cycles of treatment
Trial: 15228063
Drug: Jellyfish sting
RxNorm normalized name: zinc acetate 0.001 mg in 1 mL TOPICAL POWDER, FOR SUSPENSION [Advanced Jellyfish Sting Kit]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jellyfish sting inhibitor (Nidaria Technology Ltd, Jordan Valley, Israel)
Trial: 7644244
Drug: H-wave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-wave therapy (HWT) at various frequencies (2-60 Hz)
Trial: 752864
Drug: Weekly applications
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly applications of BCG
Trial: 15305182
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (Control)
Trial: 16115341
Drug: Daily antioxidant
RxNorm normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg Se, 20 mg Zn)
Trial: 16115341
Drug: Daily antioxidant
RxNorm normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antioxidant supplementation
Trial: 28017166
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural steroid injections
Trial: 11805628
Drug: Saline trigger-point
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline trigger-point injections
Trial: 8815273
Drug: Benazepril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10-20 mg once daily)
Trial: 8815273
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg 1-2 times daily)
Trial: 6993706
Drug: Single 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 3-g oral dose of amoxicillin trihydrate
Trial: 6993706
Drug: Conventional ten-day
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ten-day courses of oral ampicillin sodium
Trial: 11044538
Drug: Combination pill
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pill
Trial: 27649778
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg caffeine
Trial: 17972452
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel (APG) and activated platelet-poor plasma (PPP) treatment
Trial: 9562353
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 40 mU x m(‐2) x min(‐1) with 20% glucose to maintain euglycaemia
Trial: 14995946
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl infusion (control)
Trial: 2509305
Drug: Estrogen cream
RxNorm normalized name: ESTRIOL 4 mg in 85 g / ESTRADIOL 1 mg in 85 g TRANSDERMAL CREAM [BiEST 5.0 Estrogen Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen cream (B)
Trial: 183788
Drug: LF 178
RxNorm normalized name: HYDROXYPROPYL CELLULOSE LF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF 178 (200 to 400 mg daily for 1 to 18 months)
Trial: 25440329
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg (group B)
Trial: 25440329
Drug: No atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No atorvastatin (group C)
Trial: 17039216
Drug: Back School
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back School treatment
Trial: 11529534
Drug: Intranasal sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sedation with midazolam
Trial: 9101306
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (nifedipine or nicardipine)
Trial: 12805339
Drug: RSR13 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSR13 plus cranial radiation therapy (30 Gy in 10 fractions of 3 Gy each).
Trial: 12409685
Drug: Antidepressants (imipramine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (imipramine, phenelzine, L-deprenyl, mianserin, desipramine)
Trial: 7921519
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nicorandil
Trial: 2945420
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nicorandil
Trial: 2534416
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nicorandil
Trial: 3048155
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg, twice daily)
Trial: 26083656
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose
Trial: 26614143
Drug: Injection lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection lignocaine 0.2 mg/kg
Trial: 3560070
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg metergoline
Trial: 3560070
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bromoergocriptine
Trial: 30407744
Drug: Needle injection
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle injection
Trial: 28651515
Drug: Adjunctive corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive corticosteroid treatment
Trial: 24298765
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Jing-well points on the differentiated meridians and temple-three-needle therapy
Trial: 12953031
Drug: On-line convective
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-line convective treatments (HF and HDF)
Trial: 23065392
Drug: Crude methanolic
RxNorm normalized name: methanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crude methanolic extracts of Euphorbia helioscopia at concentrations of 12.5 mg/ml, 25 mg/ml, and 50 mg/ml
Trial: 23065392
Drug: Methanolic and
RxNorm normalized name: methanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methanolic and aqueous extracts of Euphorbia helioscopia at concentrations ranging from 100 to 500 mg/ml
Trial: 20848384
Drug: Illustration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illustration group (detailed illustrations regarding medication use)
Trial: 20848384
Drug: Oral group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral group (standard oral postoperative instructions)
Trial: 11322350
Drug: Tolterodine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine, 2 mg twice daily
Trial: 15478523
Drug: Tolterodine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine at self-selected doses (SSDs)
Trial: 15478523
Drug: Oxybutynin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin at self-selected doses (SSDs)
Trial: 7882730
Drug: RYHB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RYHB vaccine (20 micrograms per dose)
Trial: 7882730
Drug: PHB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHB vaccine (20 micrograms per dose)
Trial: 20478681
Drug: Supervised Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised Exercise Therapy (SET)
Trial: 30025713
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shockwave therapy given over 2 weeks
Trial: 24806159
Drug: Letermovir 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir 60 mg per day
Trial: 10604643
Drug: Fosfomycin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin treatment within the first two days of illness
Trial: 10604643
Drug: Fosfomycin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin treatment on the second day of illness
Trial: 10604643
Drug: Fosfomycin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin treatment on and after the third day of illness
Trial: 10604643
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial agents
Trial: 6764935
Drug: Tryptophan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (3 grams daily)
Trial: 26076313
Drug: Assist (talk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assist (talk about quitting or recommend stop‐smoking medications or recommend counseling)
Trial: 21890583
Drug: Alcohol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.7 g/kg males; 0.63 g/kg females)
Trial: 15214221
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of implants with full-arch prostheses after 9 to 18 days
Trial: 15214221
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of implants with full-arch prostheses after 2.5 to 5.1 months
Trial: 7702447
Drug: Focal interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal interpersonal therapy
Trial: 22133036
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) therapy
Trial: 32776
Drug: Lorazepam (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (3.2 mg twice daily)